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proteins. This review will focus on the regulation of skeletal myogenesis by MyoD and related myogenic HLH proteins.
Expression ofa Single Gene is Sufficient to Activate Myogenesis
The notion that a small number ofgenes, or a single gene, was capable of orchestrating an entire program of differentiation was postulated by Holtzer and colleagues based on the kinetics of the inhibition of myogenesis and erythrogenesis by the thymidine analog 5-bromo-2'-deoxyuridine (BrdU) (1) (2) (3) . The critical observation that a large percentage of cells of the mouse fibroblast line C3HlOTl/2 (lOTl/2 cells) could be stably converted to myoblasts by a brieftreatment with the DNA demethylating agent 5-azacytidine (4, 5) provided additional evidence that a single gene was sufficient to activate myogenesis. This was directly demonstrated by genomic transfection experiments in which transfection of DNA isolated from myoblasts could convert lOT 1/2 cells to muscle at a frequency consistent with the transfer of a single myogenic locus, whereas transfection with lOT1/2 cell DNA failed to convert lOT1/2 cells to muscle (6, 7) .
Subtraction hybridization screening was then used to identify myoblast-specific transcripts. One of the cDNAs that was expressed only in skeletal muscle was capable of directly converting l OT1/2 cells to myoblasts without the necessity for treatment with azacytidine (8) . This gene, MyoD, met the requirement for sufficiency ofa single locus to convert a cell to a myoblast. To date, four different, but related (see below) genes have been cloned from muscle cells: MyoD, myogenin, myf-5, and MRF4/Herculin/Myf6 (8) (9) (10) (11) (12) (13) (14) . Each is sufficient to activate the myogenic program when expressed in a nonmuscle cell line and together they comprise the MyoD family of myogenic regulatory genes. At present, while quantitative differReceivedfor publication 9 November 1990. I. Abbreviations used in this paper: bHLH, basic helix-loop-helix; BrdU, 5-bromo-2'-deoxyuridine; HLH, helix-loop-helix, MCK, muscle creatine kinase. ences have been demonstrated (15) , it is unclear whether they have qualitatively different functions.
The question arises, however, as to whether fibroblast cell lines, such as lOT 1/2, are cryptically committed to myogenesis and the activity of MyoD and related genes is only permissive for the expression of the muscle phenotype. This is apparently not the case because muscle specific genes can be activated by forced expression of MyoD (using a strong viral promoter) in a large number of cell lines, including neuroblastoma, melanoma, hepatoma, and teratocarcinoma (16) . In addition, primary cultures of retinal pigment epithelial cells, chondrocytes, and dermal fibroblasts can be converted to skeletal muscle cells that are morphologically and biochemically indistinguishable from normal muscle cells (17) . To the extent that it has been analyzed, the endogenous differentiation program of these converted cells has been extinguished. This suggests not only that MyoD is sufficient to activate the myogenic program without the a priori cooperation of other muscle-specific factors, but also that the myogenic regulatory genes are capable of interacting with and suppressing the tissue-specific regulatory factors of the other cell types tested, even though these cells would not ordinarily express the myogenic genes.
MyoD is a Muscle-specific Transcription Factor
In vitro gel shift assays have demonstrated that MyoD protein binds DNA that contains a core consensus sequence specified by CANNTG (18) . Paired MyoD binding sites are essential parts of several characterized enhancers of muscle-specific genes (18) (19) (20) (21) . MyoD binds cooperatively to the paired sites in the muscle creatine kinase (MCK) enhancer and deletion analysis has shown that the NH2-terminal 50 amino acids are necessary for this cooperativity (19) . In enhancers that contain two MyoD binding sites both are necessary for full enhancer activity, arguing for the functional importance ofcooperative binding. In contrast, some enhancers, such as that for alpha-cardiac actin, contain a single identified MyoD binding site (22) . In this case the adjacent CArG and SPl binding sites can functionally substitute for the second MyoD binding site, because the enhancer activity is dependent on the presence of all three sites.
The predicted protein sequence ofMyoD shares a region of homology with the other myogenic regulatory genes as well as with other tissue-specific and ubiquitous transcription factors. Mutational analysis ofMyoD has shown that this region is both necessary and sufficient for biological activity and for sequence-specific DNA binding (23) . This region has the potential to form two amphipathic alpha-helices separated by a nonhelical loop, referred to as the (HLH) motif (24). Many members ofthe HLH protein family, including the MyoD family of myogenic regulatory genes, have a region rich in basic amino acids that is immediately amino-terminal to the HLH domain, which we will refer to as basic helix-loop-helix (bHLH) proteins. Murre et al. (25) demonstrated that tissue-specific bHLH proteins form heterodimers with the protein products of a ubiquitously expressed bHLH gene, E2A. The E2A gene, by differential splicing, encodes for at least three different bHLH proteins, E12, E47, and ITF1 (25, 26) . These three proteins bind to the kappa-E2 enhancer ofthe kappa light chain immunoglobulin gene with a specificity for the same core CANNTG motif as MyoD. MyoD and related myogenic bHLH proteins have a relatively weak binding affinity to the CANNTG sites in the MCK enhancer, whereas the heterodimer formed with an E2A protein binds with much higher affinity (25, 27, 28) . A detailed mutagenesis study ofthe MyoD and E2A proteins showed that the HLH domain mediates protein-protein interactions, whereas the basic region interacts with DNA (28, 29) .
Four separate genes have been identified that code for related bHLH proteins that bind to the E-boxes of the immunoglobulin enhancers: TFE3 (30), ITF2 (26) , TFEB (31) , and E2A (24). All four genes are transcribed in both B cells and non-B cells. In this review we will focus on the E2A proteins because their role in myogenesis has been most extensively studied. It should be stressed, however, that these other members of the E-box binding subfamily ofbHLH proteins may provide additional combinatorial complexity to the regulation of the myogenic bHLH proteins.
Fusion proteins utilizing the Gal 4 DNA binding domain (which can bind to Gal 4 binding sites upstream of a reporter chloramphinicol acetyl transferase [CAT] gene) fused to portions of either MyoD (Weintraub, H., unpublished data), myf-5, or the E2A proteins (26, 32) have been used to demonstrate that these bHLH proteins have an activation domain separate from the bHLH region. In the case ofMyoD and E-box binding proteins ITFl and ITF2, the activation domain maps to the amino-terminal region, the same region in MyoD that participates in cooperative binding. For myf-5 both the amino-terminal and carboxyterminal domains share function as activation domains.
Analysis ofthe binding site preferences for MyoD and E2A proteins shows that each has a slightly different preferred halfsite, giving homo-and heterodimers slightly different preferred binding sequences (33) . A simple combinatorial model, therefore, would use the availability of a dimerization partner to target a preferred binding site and the bound complex would position the activation domains to interact with proteins that mediate transcription. Mutations of the MyoD basic region, however, showed that, compared to wild-type MyoD, some mutants bind with similar or better affinity to the MyoD binding sites in the MCK enhancer but do not activate transcription (28) , arguing that the NH2-terminal activation domain of MyoD is usually "hidden" from the transcriptional machinery and that the "exposure" of the activation region can be regulated independently of DNA binding. This is supported by experiments where the Ga I 4-MyoD fusion protein is used to activate a {Gal-CAT reporter. Here Competition between HLH Proteins Regulates Myogenesis Replicating myoblast cell lines express both myogenic bHLH proteins and the E2A proteins in their nucleus, yet they fail to activate the myogenic program. Whereas MyoD activates some myoblast-specific genes in the replicating cell, the genes characteristic of terminal differentiation are activated only after the removal ofgrowth factors (8) . One possible mechanism ofnegatively regulating the activity ofthe myogenic bHLH proteins is by decreasing the available pool of E2A proteins through dimerization with the HLH protein Id (34) . This protein shares the HLH domain but lacks an adjacent basic region. It has been demonstrated in vitro that Id dimerizes with the E2A protein products with a relatively high affinity, using the HLH region as a dimerization motif. By competing for HLH dimerization regions Id can prevent the formation of MyoD:E2A protein oligomers. Because Id lacks a region equivalent to the DNA binding domain ofthe bHLH proteins, Id containing heterooligomers do not bind the core CANNTG sequence. In vivo it has been demonstrated that forced expression of Id protein will inhibit the activity of MyoD on a reporter gene and inhibit myogenic conversion of C2 myoblasts. Similar inhibition is attained by overexpressing a MyoD protein with a deletion of the basic region (28) , supporting the interpretation that Id inhibits the activity ofthe myogenic HLH proteins by competing with them for dimerization with the E2A proteins. Like the E2A proteins, Id is expressed in a wide variety of cell types suggesting that a similar mechanism is used to modulate bHLH activity in other lineages. In many of these lineages, including muscle, when the cells are induced to differentiate the level of Id mRNA declines (34 MyoD expression is repressed by trans acting factors in primary fibroblasts. The MyoD gene is located on the short arm of human chromosome 11 (39) . When chromosome 11 is transferred from primary human fibroblasts to lOT1/2 cells or B78 melanoma cells, the human MyoD locus on chromosome 11 is activated (40) , and, in lOTl/2 cells, autoactivation also leads to the turn-on of the mouse MyoD gene. In contrast, in heterokaryons and whole-cell hybrids between fibroblasts and lOT 1/ 2 cells the MyoD locus is not activated until specific human chromosomes are lost, suggesting that an important regulatory mechanism is the suppression of MyoD transcription in trans mediated by loci on separate chromosomes, probably on chromosomes 4 and 8 (40) . When the transferred human chromosome 11 is lost, the endogenous mouse myogenic regulatory genes can maintain their own expression.
The MyoD gene contains a CpG island that is virtually devoid of methylation in normal tissues and primary cell cultures (41) . However, in the establishment ofcell lines this CpG island becomes heavily methylated and, presumably, the MyoD gene becomes inactivated by this cis acting mechanism. It is possible that this methylation is selected for because ofthe loss or inactivation of trans acting repressors of MyoD transcription. lOT In contrast to the effect of serum, TGF-beta blocks myogenesis in serum free medium (43, 44) , where Id expression is turned off. Whereas its activity in part can be attributed to the decline in the levels of MyoD and myogenin, TGF-beta will block the activity of myogenin even when myogenin expression is maintained from a transfected expression vector (43, 44) . In this latter case, nuclear extracts demonstrate the presence of myogenin:E2A complexes that bind the MCK enhancer sequences in gel retardation assays (43) . This would suggest that TGF-beta is working through a mechanism distinct from preventing heterooligomer formation, either by preventing DNA binding in vivo or preventing the ability of the bound ocmplex to activate transcription. Activated ras and overexpression offos also inhibit both the transcription of the myogenic bHLH genes and interfere with the activity of their proteins (45) . The effect of these agents on transcription of MyoD could be a manifestation of the interference with MyoD protein function, because the MyoD family of bHLH genes use positive autoregulatory feedback to maintain high levels of expression. It is not yet known whether ras, fos, and TGF-beta mediate their effects at the same or different steps in the function of myogenic bHLH proteins. None of these "reagents" inhibits the ability of Gal-MyoD fusion proteins to activate a Gal-CAT reporter construct (Weintraub, H., and A. B. Lassar, unpublished data), suggesting that inhibition occurs at a step before transcriptional activation, perhaps DNA binding.
The thymidine analogue BrdU blocks myogenic differentiation when incorporated into the DNA ofthe replicating myoblast apparently without effecting the ability of the MyoD family of bHLH proteins to activate transcription of the muscle structural genes (46) . Transcription of MyoD and myogenin is extinguished in BrdU-substituted cells, but forced expression of MyoD in a BrdU-substituted cell will activate both myogenin and the genes of terminal differentiation. The endogenous MyoD gene, however, remains insensitive to trans activation, indicating that flrdU is blocking at a level that is upstream, either in cis or trans, of the MyoD gene. The fact that the effect ofBrdU on MyoD transcription is reversible provides evidence that the commitment to the muscle lineage is not just maintained by the positive autoregulatory circuit of the myogenic bHLH genes because these genes are turned off in the presence of BrdU. Instead, another element, again either in cis or trans, must provide a memory of the commitment to make muscle.
The myc proteins also contain a bHLH domain and c-myc binds to the core CANNTG binding sequence of the other bHLH proteins expressed in skeletal muscle (47) . The myc proteins have not been shown to dimerize in vitro with the E2A proteins, any of the MyoD family of bHLH proteins, or with Id. C-myc is expressed in skeletal myoblasts and shows a decline in steady-state mRNA levels when myoblasts are induced to differentiate (48) . Overexpression of c-myc can inhibit myogenesis (49) . The mechanism by which MyoD and c-myc interact is not understood, but it is interesting to note that the two also play antagonistic roles in regulating cell cycle where the HLH domain of MyoD is thought to be functionally important (see above).
As more is learned about the regulation ofMyoD activity it will be interesting to map the activity of the different steps of bHLH function in primary tumors 
